Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Moucari

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Gastroenterologie Clinique Et Biologique|November 25, 2010
[HBsAg seroclearance: prognostic value for the response to treatment and the long-term outcome]R Moucari, P Marcellin
Journal of Viral Hepatitis|July 5, 2016
Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patientsM Martinot-Peignoux, M Lapalus, S Maylin, et al.
Journal of Viral Hepatitis|May 22, 2010
Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patientsR Moucari, N Boyer, M-P Ripault, et al.
Gut|January 26, 2008
Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factorsR Moucari, P-E Rautou, D Cazals-Hatem, et al.
Journal of Viral Hepatitis|October 15, 2013
IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patientsQ Zhang, M Lapalus, T Asselah, et al.
Gut|August 13, 2009
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4R Moucari, M-P Ripault, M Martinot-Peignoux, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Gastroenterologie Clinique Et Biologique|November 25, 2010
[HBsAg seroclearance: prognostic value for the response to treatment and the long-term outcome]R Moucari, P Marcellin
Journal of Viral Hepatitis|July 5, 2016
Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patientsM Martinot-Peignoux, M Lapalus, S Maylin, et al.
Journal of Viral Hepatitis|May 22, 2010
Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patientsR Moucari, N Boyer, M-P Ripault, et al.
Gut|January 26, 2008
Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factorsR Moucari, P-E Rautou, D Cazals-Hatem, et al.
Journal of Viral Hepatitis|October 15, 2013
IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patientsQ Zhang, M Lapalus, T Asselah, et al.
Gut|August 13, 2009
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4R Moucari, M-P Ripault, M Martinot-Peignoux, et al.
Pageof 1